MedUniver.com - Все по медицине
  МедУнивер - MedUniver.com Все разделы сайта Видео по медицине Книги по медицине Форум консультаций врачей  
  Главная Видео уроки Книги  
Рекомендуем:
Обшая онкология:
Онкология
Общие вопросы онкологии
Детская онкология
Генетика рака - опухолей
Химиотерапия опухолей
Частная онкология:
Опухоли кожи
Опухоли головы и шеи
Опухоли легких и средостения
Опухоли молочной железы
Опухоли органов ЖКТ
Опухоли мочеполовой системы
Онкогинекология
Саркомы костей и мягких тканей
Опухоли крови:
Острые лейкозы
Хронические лейкозы
Макроглобулинемии
Миелодиспластические синдромы (МДС)
Книги по онкологии
Видео по онкологии
Лимфомы
Форум
 

Авторы трудов (статей) использованные при подготовке материалов по раку молочной железы

Сокращения использованные в статьях:

  1. АДФ — аденозиндифосфат
  2. АИХ — аменорея, индуцированная химиотерапией
  3. ГнРГ — гонадотропин-рилизинг гормон
  4. ГР — гомологичная рекомбинация
  5. ДИ — доверительный интервал
  6. ДНК — дезоксирибонуклеиновая кислота
  7. ИА — ингибиторы ароматазы
  8. ИМТ — индекс массы тела
  9. иРМЖ — ипсилатеральный рак молочной железы кРМЖ — контралатеральный рак молочной железы
  10. КСЯ — контролируемая стимуляция яичников мРНК — матричная рибонуклеиновая кислота МРР — местно-регионарный рецидив
  11. МРТ — магнитно-резонансная томография
  12. ОР — относительный риск
  13. ОСО — органосохраняющая операция
  14. ПК — протоковая карцинома
  15. ПМЛТ — постмастэктомическая лучевая терапия
  16. ПНЯ — преждевременная недостаточность яичников пПО — полный патоморфологический ответ
  17. ПФЯ — подавление функций яичников РМЖ — рак молочной железы
  18. РНК — рибонуклеиновая кислота
  19. тнРМЖ — тройной негативный рак молочной железы
  20. УЗИ — ультразвуковое исследование ЭТ — эндокринная терапия
  21. ADM (от англ, acellular dermal matrix) — бесклеточная кожная матрица
  22. DRFI (от англ, distant recurrence-free interval) — выживаемость без отдаленных рецидивов
  23. EORTC (от англ. European Organization for Research and Treatment of Cancer) — Европейская организация по исследованию и лечению рака
  24. ER (от англ, estrogen receptor) — рецептор эстрогена
  25. ESMO (от англ. European Society for Medical Oncology) — Европейское общество медицинской онкологии
  26. HER (от англ, human epidermal growth factor receptor) — рецептор эпидермального фактора роста
  27. IBCSG (от англ. International Breast Cancer Study Group)
  28. Международная группа по изучению рака молочной железы
  29. LD (от лат. latissimus dorsi) — широчайшая мышца спины
  30. NCCN (от англ. National Comprehensive Cancer Network) — Национальная комплексная онкологическая сеть
  31. РАМ50 (от англ, prediction analysis of the microarrays) — количественный анализ 50 генов с помощью полимеразной цепной реакции в режиме реального времени
  32. PARP (от англ. poly-(ADP-ribose) polymerases) — поли-(АДФ-рибоза)-полимераза
  33. PgR (от англ, progesterone receptor) — рецептор прогестерона
  34. PI3K (от англ, phosphoinositide 3-kinase) — фосфоинозитид-3-киназа
  35. ROR-PT (от англ, risk of recurrence score) — балл риска рецидива
  36. SEER (от англ. Surveillance, Epidemiology, and End Results) — анализ течения, распространенности и исходов злокачественных новообразований

В ходе подготовки статей по раку молочной железы для пользователей сайта МедУнивер использованы труды следующих авторов:

  1. Ford D., Easton D.F., Stratton М. et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium // Am. J. Hum. Genet. 1998. Vol. 62. P. 676-689.
  2. Roa B.B., Boyd A.A., Volcik K., Richards C.S. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 // Nat. Genet. 1996. Vol. 14. P. 185-187.
  3. Paul A., Paul S. The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers // Front. Biosci. (Landmark Ed.). 2014. Vol. 19. P. 605-618.
  4. King M.C., Marks J.H., Mandell J.B.; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 // Science. 2003. Vol. 302. P. 643-646.
  5. Walsh Т, Casadei S., Lee M.K. et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing// Proc. Natl Acad. Sci. USA. 2011. Vol. 108. P. 18 032-18 037.
  6. Kuchenbaecker K.B., Hopper J.L., Barnes D.R. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers //JAMA. 2017. Vol. 317. P. 2402-2416.
  7. Mersch J., Jackson M.A., Park M. et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian // Cancer. 2015. Vol. 121. P. 269-275.
  8. Easton D.F., Pharoah P.D., Antoniou A.C. et al. Gene-panel sequencing and the prediction of breast-cancer risk //N. Engl. J. Med. 2015. Vol. 372. P. 2243-2257.
  9. Rosenberg S.M., Ruddy K.J., Tamimi R.M. et al. BRCA1 and BRCA2 mutation testing in young women with breast cancer // JAMA Oncol. 2016. Vol. 2. P. 730-736.
  10. Xu X., Weaver Z., Linke S.P. et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells // Mol. Cell. 1999. Vol. 3. P. 389-395.
  11. Yu V.P., Koehler M., Steinlein C. et al. Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation // Genes Dev. 2000. Vol. 14. P. 1400-1406.
  12. Foulkes W.D., Shuen A.Y. In brief: BRCA1 and BRCA2 // J. Pathol. 2013. Vol. 230. P. 347-349.
  13. Pardo B., Gomez-Gonzalez B., Aguilera A. DNA repair in mammalian cells: DNA double-strand break repair: how to fix a broken relationship // Cell. Mol. Life Sci. 2009. Vol. 66. P. 1039-1056.
  14. Venkitaraman A.R. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment // Annu. Rev. Pathol. 2009. Vol. 4. P. 461-487.
  15. Roy R., Chun J., Powell S.N. BRCA1 and BRCA2: different roles in a common pathway of genome protection // Nat. Rev. Cancer. 2012. Vol. 12. P. 68-78.
  16. Yang H., Jeffrey P.D., Miller J. et al. BRCA2 function in DNA binding and recombination from a BRCA2-DSSl-ssDNA structure // Science. 2002. Vol. 297. P. 1837-1848.
  17. Jensen R.B., Carreira A., Kowalczykowski S.C. Purified human BRCA2 stimulates RAD51-mediated recombination //Nature. 2010. Vol. 467. P. 678-683.
  18. Wang B., Matsuoka S., Ballif B.A. et al. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response // Science. 2007. Vol. 316. P. 1194-1198.
  19. Chen L., Nievera C.J., Lee A.Y., Wu X. Cell cycle-dependent complex formation of BRCA1. CtIP. MRN is important for DNA double-strand break repair // J. Biol. Chem. 2008. Vol. 283. P. 7713-7720. DOI: https://doi.org/10.1074/jbc. M710245200 Epub 2008 Jan 2.
  20. Zhang E, Maj., Wu J. et al. PALB2 links BRCA1 and BRCA2 in the DNA-damage response // Cure. Biol. 2009. Vol. 19. P. 524-529.
  21. Tutt A., Bertwistle D., Valentine J. et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences // EMBO J. 2001. Vol. 20. P. 4704-4716.
  22. Turner N., Tutt A., Ashworth A. Hallmarks of‘ «BRCAness» in sporadic cancers // Nat. Rev. Cancer. 2004. Vol. 4. P. 814-819.
  23. Caestecker K.W., Van de Walle G.R. The role of BRCA1 in DNA double-strand repair: past and present // Exp. Cell Res. 2013. Vol. 319. P. 575-587.
  24. Osorio A., de la Hoya M., Rodriguez-Lopez R. et al. Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer // Int. J. Cancer. 2002. Vol. 99. P. 305-309.
  25. Cavalli L.R., Singh B., Isaacs C. et al. Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer // Cancer Genet. Cytogenet. 2004. Vol. 149. P. 38-43.
  26. Konishi H, Mohseni M, Tamaki A et al. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells // Proc. Natl Acad. Sci. USA. 2011. Vol. 108. P. 17 773-17 778.
  27. Ludwig T, Chapman D.L., Papaioannou VE., Efstratiadis A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brcal, Brca2, Brcal/Brca2, Brcal/p53, and Brca2/p53 nullizygous embryos // Genes Dev. 1997. Vol. 11. P. 1226-1241.
  28. Evers B., Jonkers J. Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects // Oncogene. 2006. Vol. 25. P. 5885-5897.
  29. Leegte B., van der Hout A.H., Deffenbaugh A.M. et al. Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations // J. Med. Genet. 2005. Vol. 42. P. e20.
  30. Spannuth W.A., Thaker Р.Н., Sood A.K. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer // Am. J. Obstet. Gynecol. 2007. Vol. 196. P. e6-e9.
  31. Greenblatt M.S., Chappuis P.O., Bond J.P. et al. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution // Cancer Res. 2001. Vol. 61. P. 4092-4097.
  32. Holstege H., Joosse S.A., van Oostrom C.T. et al. High incidence of proteintruncating TP53 mutations in BRCAl-related breast cancer // Cancer Res. 2009. Vol. 69. P. 3625-3633.
  33. Sedic M., Kuperwasser C. BRCAl-hapoinsufficiency: unraveling the molecular and cellular basis for tissue-specific cancer // Cell Cycle. 2017. Vol. 15. P. 621-627.
  34. Monteiro A.N. BRCAl: the enigma of tissue-specific tumor development // Trends Genet. 2003. Vol. 19. P. 312-315.
  35. Elledge SJ., Amon A. The BRCA1 suppressor hypothesis: an explanation for the tissue-specific tumor development in BRCA1 patients // Cancer Cell. 2002. Vol. 1. P. 129-132.
  36. Sedic M., Skibinski A., Brown N. et al. Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence // Nat. Commun. 2015.Vol. 6. Article ID 7505.
  37. Palacios J., Robles-Frias M.J., Castilla M.A. et al. The molecular pathology of hereditary breast cancer // Pathobiology. 2008. Vol. 75. P. 85-94.
  38. Mavaddat N., Barrowdale D., Andrulis I.L. et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) // Cancer Epidemiol. Biomarkers Prev. 2012. Vol. 21. P. 134-147.
  39. Lakhani S.R., Van De Vijver M.J., Jacquemier J. et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2 //J. Clin. Oncol. 2002. Vol. 20. P. 2310-2318.
  40. Honrado E., Benitez J., Palacios J. Histopathology of BRCA1- and BRCA2-associated breast cancer // Crit. Rev. Oncol. Hematol. 2006. Vol. 59. P. 27-39.
  41. Atchley D.P., Albarracin C.T., Lopez A. et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer // J. Clin. Oncol. 2008. Vol. 26. P. 4282-4288.
  42. Molyneux G., Smalley M.J. The cell of origin of BRCA1 mutation-associated breast cancer: a cautionary tale of gene expression profiling //J. Mammary Gland Biol. Neoplasia. 201 1. Vol' 16. P. 51-55.
  43. Molyneux G., Geyer F.C., Magnay F.A. et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells // Cell Stem Cell. 2010. Vol. 7. P. 403-417.
  44. Lim E., Vaillant E, Wu D. et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers // Nat. Med. 2009. Vol. 15. P. 907-913.
  45. Saal L.H., Gruvberger-Saal S.K., Persson C. et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair // Nat. Genet. 2008. Vol. 40. P. 102-107.
  46. Eerola H., Heikkila P, Tamminen A. et al. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families // Breast Cancer Res. 2005. Vol. 7. P. R93-R100.
  47. Lewin R., Sulkes A., Shochat T. et a], Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations // Breast Cancer Res. Treat. 2016.Vol. 157. P. 511-516.
  48. Halpern N., Sonnenblick A., Uziely B. et al. Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer // Int. J. Cancer. 2017. Vol. 140. P. 2145-2149.
  49. 4Goodwin P.J., Phillips K.A., West D.W. et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study //J. Clin. Oncol. 2012. Vol. 30. P 19-26.
  50. Rennert G., Bisland-Naggan S., Barnett-Griness O. et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations // N. Engl. J. Med. 2007.Vol. 357. P. 115-123.
  51. Huzarski T, Byrski T, Gronwald J. et al. Ten-year survival in patients with BRCA1-negative and BRCAl-positive breast cancer // J. Clin. Oncol. 2013. Vol. 31. P. 3191-3196.
  52. 5E1-Tamer M., Russo D., Troxel A. et al. Survival and recurrence after breast cancer in BRCA1/2 mutation carriers // Ann. Surg. Oncol. 2004. Vol. 11. P. 157-164.
  53. Veronesi A., de Giacomi C., Magri M.D. et al. Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases // BMC Cancer. 2005.Vol. 5. P. 70.
  54. Brekelmans С.Т., Seynaeve С., Menke-Pluymers М. et al. Survival and prognostic factors in BRCA 1-associated breast cancer // Ann. Oncol. 2006. Vol. 17. P. 391-400.
  55. Arun B., Bayraktar S., Liu D.D. et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience //J. Clin. Oncol. 2011. Vol. 29. P. 3739-3746.
  56. Bonadona V, Dussart-Moser S., Voirin N. et al. Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review // Breast Cancer Res. Treat. 2007. Vol. 101. P. 233-245.
  57. Foulkes W.D., Chappuis P.O., Wong N. et al. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome // Ann. Oncol. 2000. Vol. 11. P. 307-313.
  58. Moller P, Borg A., Evans D.G. et al. Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy // Int. J. Cancer. 2002. Vol. 101. P. 555-559.
  59. Robson M.E., Chappuis P.O., Satagopan J. et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/ BRCA2 mutation status and administration of adjuvant treatment // Breast Cancer Res. 2004. Vol. 6. P. R8-R17.
  60. Chalasani P, Livingston R. Differential chemotherapeutic sensitivity for breast tumors with «BRCAness»: a review // Oncologist. 2013. Vol. 18. P. 909-916.
  61. Bayraktar S., Gluck S. Systemic therapy options in BRCA mutation-associated Breast cancer // Breast Cancer Res. Treat. 2043. Vol. 135. P. 355-366.
  62. Zhong Q„ Peng H.L., Zhao X. et al. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis // Clin Cancer Res. 2015. Vol. 21. P. 211-220.
  63. van den Broek A.J., Schmidt M.K., van’t Veer L.J. et al. Worse breast cancer prognosis of BRCA1/ BRCA2 mutation carriers: what’s the evidence? A systematic review with meta-analysis//PLoS One. 2015. Vol. 10 Article ID e0120189.
  64. Lee E.H., Park S.K., Park B. et al. Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis // Breast Cancer Res. Treat. 2010. Vol. 122. P. 11-25.
  65. Baretta Z., Mocellin S„ Goldin E. et al. Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis // Medicine. 2016. Vol. 95. P. e4975.
  66. Tassone P, Tagliaferri P, Perricelli A. et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells // Br. J. Cancer. 2003. Vol. 88. P. 1285-1291.
  67. Quinn J.E., Kennedy R.D., Mullan P.B. et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis // Cancer Res. 2003. Vol. 63. P 6221-6228.
  68. Kennedy R.D., Quinn J.E., Mullan P.B. et al. The role of BRCA1 in the cellular response to chemotherapy // J. Natl Cancer Inst. 2004. Vol. 96. P. 1659-1668.
  69. Foulkes WD. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis // Fam. Cancer. 2006. Vol. 5. P. 135-142.
  70. Kriege М., Seynaeve С., Meijers-Heijboer Н. et al. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers // J. Clin. Oncol. 2009. Vol. 27. P. 3764-3771.
  71. Byrski T, Gronwahl J., Huzarski T. et al. Pathologic complete response rates in young women with BRCAl-positive breast cancers after neoadjuvant chemotherapy //J. Clin. Oncol. 2010. Vol. 28. P. 375-379.
  72. Byrski T, Dent R., Blecharz P. et al. Results of a phase II open-label, nonrandomized trial of cisplatin chemotherapy in patients with BRCAl-positive metastatic breast cancer // Breast Cancer Res. 2014. Vol. 14. P. R110.
  73. Wysocki P.J., Korski K., Lamperska K. et al. Primary resistance to docetaxelbased chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations // Med. Sci. Monit. 2008. Vol. 14. P. SC7-SC10.
  74. Byrski T, Gronwald J., Huzarski T. et al. Response to neo-adjuvant chemotherapy in women with BRCAl-positive breast cancers // Breast Cancer Res. Treat. 2008. Vol. 108. P. 289-296.
  75. Kriege M., Jager A., Hooning MJ. et aL The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers // Cancer. 2012.Vol. 118. P. 899-907.
  76. Raphael J., Mazouni C., Caron O. et al. Should BRCA2 mutation carriers avoid neoadjuvant chemotherapy? // Med. Oncol. 2014. Vol. 31. P. 850.
  77. Paluch-Shimon S., Friedman E., Berger R. et al. Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers // Breast Cancer Res. Treat. 2016. Vol. 157. P. 157-165.
  78. Esteller M., Silva J.M., Dominguez G. et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors // J. Natl Cancer Inst. 2000. Vol. 92. P. 564-569.
  79. Turner N.C., Reis-Filho J.S., Russell A.M. et al. BRCA1 dysfunction in sporadic basal-like breast cancer // Oncogene. 2007. Vol. 26. P. 2126-2132.
  80. Carey L., Winer E., Viale G. et al. Triple-negative breast cancer: disease entity or title of convenience? // Nat. Rev. Clin. Oncol. 2010. Vol. 7. P. 683-692.
  81. Curigliano G., Goldhirsch A. The triple-negative subtype: new ideas for the poorest prognosis breast cancer //J. Natl Cancer Inst. Monogr. 2011. Vol. 2011. P. 108-110.
  82. Telli M.L., Jensen K.C., Vinayak S. et al. Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105 //J. Clin. Oncol. 2015. Vol. 33. P. 1895-1901.
  83. Telli M.L., Timms K.M., Reid J. et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer // Clin. Cancer Res. 2016. Vol. 22. P. 3764-3773.
  84. Telli M., McMillan A., Ford J.M. et al. Homologous recombination deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple negative breast cancer (TNBC): a pooled analysis // Cancer Res. 2016. Vol. 76, N 4. Suppl. Abstr. P3-07-12.70.Kriege М., Seynaeve С., Meijers-Heijboer Н. et al. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers // J. Clin. Oncol. 2009. Vol. 27. P. 3764-3771.
  85. Isakoff S.J., Mayer E.L., Не L. et al. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triplenegative breast cancer // J. Clin. Oncol. 2015. Vol. 33. P. 1902-1909.
  86. Silver D.P., Richardson A.L., Eklund A.C. et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer // J. Clin. Oncol. 2010. Vol. 28. P. 1145-1153.
  87. von Minckwitz G., Schneeweiss A., Loibl S. et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial // Lancet Oncol. 2014. Vol. 15. P. 747-756.
  88. Hahnen E., Lederer B., Hauke J. et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto Randomized Clinical Trial //JAMA Oncol. 2017.Vol. 3. P. 1378-1385.
  89. Carey L.A. Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer //J. Clin. Oncol. 2010. Vol. 28. P. 361-363.
  90. Boudin L., Goncalves A., Sabatier R. et al. Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation // Bone Marrow Transplant. 2016. Vol. 51. P. 1082-1086.
  91. Pristauz G., Petru E., Stacher E. et al. Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations // Histopathology. 2010. Vol. 57. P. 877-884.
  92. Farmer H., McCabe N., Lord C.J. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy // Nature. 2005. Vol. 434. P. 917-921.
  93. Fong P.C., Boss D.S., Yap TA. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers//N. Engl. J. Med. 2009. Vol. 361. P. 123-134.
  94. Tutt A., Robson M„ Garber J.E. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial // Lancet. 2010. Vol. 376. P. 235-244.
  95. Gelmon K.A., Tischkowitz M., Mackay H. et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study // Lancet Oncol. 2011. Vol. 12. P. 852-861.
  96. 96. Kaufman B., Shapira-Frommer R., Schmutzler R.K. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation //J. Clin. Oncol. 2015. Vol. 33. P. 244-250.
  97. Dent R.A., Lindeman G.J., Clemons M. et al. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer // Breast Cancer Res. 2013.Vol. 15. P. R88.
  98. Balmana J., Tung N.M., Isakoff S.J. et al. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors // Ann. Oncol. 2014. Vol. 25. P. 1656-1663.
  99. Lee J.M., Hays J.L., Annunziata C.M. et al. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses //J. Natl Cancer Inst. 2014. Vol. 106. Article ID dju 089.
  100. Matulonis U.A., Wulf G.M., Barry W.T. et al. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer // Ann. Oncol. 2017. Vol. 28. P. 512-518.
  101. Tan A.R., Toppmeyer D., Stein M.N. et al. Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors. ASCO Meeting Abstracts //J. Clin. Oncol. 2011. Vol. 29. Absrt. 3041.
  102. Somlo G., Sparano J.A., Cigler T. et al. ABT-888 (veliparib) in combination with carboplatin in patients with stage IV BRCA-associated breast cancer. A California Cancer Consortium Trial. ASCO Meeting Abstracts // J. Clin. Oncol. 2012. Vol. 30. Abstr. 1010.
  103. Isakoff S.J., Overmoyer B., Tung N.M. et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. ASCO Meeting Abstracts // J. Clin. Oncol. 2010. Vol. 28. Abstr. 1019.
  104. Wolf D.M., Yau C., Sanil A. et al. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial // NPJ Breast Cancer. 2017. Vol. 3. P. 31.
  105. Severson T.M., Wolf D.M., Yau C. et al. The BRCAlness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting // Breast Cancer Res. 2017. Vol. 19. P. 99.
  106. Drew Y, Ledermann J., Hall G. et al. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer // Br. J. Cancer. 2016. Vol. 114. P. e21.
  107. Wilson R.H., Evans T.J., Middleton M.R. et al. A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours // Br. J. Cancer. 2017. Vol. 116. P. 884-892.
  108. Sandhu S.K., Schehnan W.R., Wilding G. et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial // Lancet Oncol. 2013. Vol. 14. P. 882-892.
  109. de Bono J., Ramanathan R.K., Mina L. et al. Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers // Cancer Discov. 2017. Vol. 7. P. 620-629.
  110. Edwards S.L., Brough R., Lord C.J. et al. Resistance to therapy caused by intragenic deletion in BRCA2 //Nature. 2008. Vol. 451. P. 1111-1115.
  111. Swisher E.M., Sakai W, Karlan B.Y. et al. Secondary BRCA1 mutations in BRCAl-mutated ovarian carcinomas with platinum resistance // Cancer Res. 2008.Vol. 68. P. 2581-2586.
  112. Bouwman P, Jonkers J. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? // Clin. Cancer Res. 2014. Vol. 20. P. 540-547.
  113. Delaloge S., Wolp-Diniz R„ Byrski T. et al. Activity of trabectedin in germline BRCAl/2-mutated metastatic breast cancer: results of an international first-in-class phase II study // Ann. Oncol. 2014. Vol. 25. P. 1152-1158.
  114. Ghouadni A., Delaloge S., Lardelli Р. et al. Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: a subset analysis of a dedicated phase II trial // Breast. 2017. Vol. 34. P. 18-23.
  115. Balmana J., Cruz C., Arun B. Anti-tumor activity of PM01183(lurbinectedin) in BRCA1/2 associated metastatic breast cancer patients; results of a single-agent phase II trial. ESMO paper // Ann. Oncol. 2016. Vol. 27. P. 68-99.
  116. Cardillo T.M., Sharkey R.M., Rossi D.L. et al. Synthetic lethality exploitation by an Anti-Trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP inhibitors in BRCAl/2-wild-type triple negative breast cancer // Clin. Cancer Res. 2017. Vol. 23. P. 3405-3415.
  117. Du Y., Yamaguchi H., Wei Y. et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors // Nat. Med. 2016. Vol' 22. P. 194-201.
  118. Zimmer J., Tacconi E.M.C., Folio C. et al. Targeting BRCA1 and BRCA2 deficiencies with G-quadruplex-interacting compounds // Mol. Cell. 2016. Vol. 61. P. 449-460.
  119. Tung N., Lin N.U., Kidd J. et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer //J. Clin. Oncol. 2016. Vol. 34. P. 1460-1468.
  120. Tung N., Battelli C., Allen B. et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel // Cancer. 2015. Vol. 121. P. 25-33.
  121. McCuaig J.M., Armel S.R., Novokmet A. et al. Routine TP53 testing for breast cancer under age 30: ready for prime time? // Fam. Cancer. 2012. Vol. 11. P. 607-613.
  122. Weller M. Predicting response to cancer chemotherapy: the role of p53 // Cell Tissue Res. 1998. Vol. 292. P. 435-445.
  123. Kappel S., Janschek E., Wolf B. et al. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family // Breast Cancer Res. Treat. 2015. Vol. 151. P. 671-678.
  124. Bridges K.A., Chen X., Liu H. et al. MK-8776, a novel chkl kinase inhibitor, radiosensitizes p53-defective human tumor cells // Oncotarget. 2016. Vol. 7. P.71 660-771 662.
  125. Hirai H., Iwasawa Y, Okada M et al. Small-molecule inhibition of Weel kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents // Mol. Cancer Ther. 2009. Vol. 8. P. 2992-3000.
  126. Markman B., Tabernero J., Krop I. et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors // Ann. Oncol. 2012. Vol. 23. P. 2399-2408.
  127. Tischkowitz M., Xia B. PALB2/FANCN: recombining cancer and Fanconi anemia // Cancer Res. 2010. Vol. 70. P. 7353-7359.
  128. Tung N., Domchek S.M., Stadler Z. et al. Counselling framework for moderatepenetrance cancer-susceptibility mutations // Nat. Rev. Clin. Oncol. 2016. Vol. 13. P. 581-588.
  129. Ferreira А.С., Suriano G., Mendes N. et al. E-cadherin impairment increases cell survival through Notch-dependent upregulation of Bcl-2 // Hum. Mol. Genet. 2012. Vol. 21. P. 334-343.
  130. Mateus A.R., Seruca R., Machado J.C. et al. EGFR regulates RhoA-GTP dependent cell motility in E-cadherin mutant cells // Hum. Mol. Genet. 2007. Vol. 16. P. 1639-1647."
  131. Mateus A.R., Simoes-Correia J., Figueiredo J. et al. E-cadherin mutations and cell motility: a genotype-phenotype correlation // Exp. Cell Res. 2009. Vol. 315. P. 1393-1402.
  132. Hearle N., Schumacher V, Menko F.H. et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome // Clin. Cancer Res. 2006. Vol. 12. P. 3209-3215.
  133. Valencia О.М., Samuel S.E., Viscusi R.K., Riall T.S., Neumayer L.A., Aziz H. The role of genetic testing in patients with breast cancer: a review // JAMA Surg. 2017. Vol. 152, N 6. P. 589-594.
  134. Gentilini O.D., Cardoso M.J., Poortmans P. Less is more. Breast conservation might be even better than mastectomy in early breast cancer patients // Breast. 2017. Vol. 35. P. 32-33.
  135. Valachis A., Nearchou A.D., Lind P. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis // Breast Cancer Res. Treat. 2014. Vol. 144, N 3. P. 443-455.
  136. Evans D.G., Harkness E.E, Plaskocinska L, Wallace A.J., Clancy T, Woodward E.R. et al. Pathology update to the Manchester Scoring System based on testing in over 4000 families //J. Med. Genet. 2017. Vol. 54, N 10. P. 674-681.
  137. Wevers M.R., Ausems M.G., Verhoef S., Bleiker E.M., Hahn D.E., Brouwer T. et al. Does rapid genetic counseling and testing in newly diagnosed breast cancer patients cause additional psychosocial distress? Results from a randomized clinical trial // Genet. Med. 2016. Vol. 18, N 2. P. 137-144.
  138. Kurian A.W, Griffith K.A., Hamilton A.S., Ward K.C., Morrow M., Katz SJ. et al. Genetic testing and counseling among patients with newly diagnosed breast cancer //JAMA. 2017. Vol. 317, N 5. P. 531-534.
  139. Yadav S., Reeves A., Campian S., Sufka A., Zakalik D. Preoperative genetic testing impacts surgical decision making in BRCA mutation carriers with breast cancer: a retrospective cohort analysis // Hered. Cancer Clin. Pract. 2017. Vol. 15. P. 11.
  140. Wevers M.R., Aaronson N.K., Bleiker E.M.A., Hahn D.E.E., Brouwer T, van Dalen T. et al. Rapid genetic counseling and testing in newly diagnosed breast cancer: patients’ and health professionals’ attitudes, experiences, and evaluation of effects on treatment decision making //J. Surg. Oncol. 2017. Vol. 116, N 8. P. 1029-1039.
  141. Shah P.D., Patil S., Dickler M.N., Offit K., Hudis C.A., Robson M.E. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: differences based on germline mutation status // Cancer. 2016. Vol. 122, N 8. P. 1178-1184.
  142. Pierce L.J., Phillips K.A., Griffith K.A., Buys S., Gaffney D.K., Moran M.S. et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy // Breast Cancer Res. Treat. 2010. Vol. 121, N 2. P. 389-398.
  143. Metcalfe K., Gershman S., Ghadirian P, Lynch H.T, Snyder C., Tung N. et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis // BMJ. 2014. Vol. 348. P g226.
  144. Metcalfe K., Gershman S., Lynch H.T, Ghadirian P, Tung N., Kim-Sing C. et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers // Br. J. Cancer. 2011. Vol. 104, N 9. P. 1384-1392.
  145. Peled A.W, Irwin C.S., Hwang E.S., Ewing C.A., Alvarado M., Esserman L.J. Total skin-sparing mastectomy in BRCA mutation carriers // Ann. Surg. Oncol. 2014. Vol. 21, N 1. P. 37-41.
  146. Lyman G.H., Temin S., Edge S.B., Newman L.A., Turner R.R., Weaver D.L. et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update //J. Clin. Oncol. 2014. Vol. 32, N 13. P. 1365-1383.
  147. Burger A., Thurtle D., Owen S., Mannu G., Pilgrim S., Vinayagam R. et al. Sentinel lymph node biopsy for risk-reducing mastectomy // Breast J. 2013. Vol. 19, N 5. P. 529-532.
  148. Бану Арун (Ванн Arun), Department of Breast Medical Oncology and Clinical Cancer Genetics Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, e-mail: barun@mdanderson.org
  149. Хэмди А. Азим (Hamdy A. Azim), Department of Clinical Oncology, Cairo University Hospital, Cairo, Egypt
  150. Хатем А. Азим младший (Hatem A. Azim Jr), Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut (AUB), Beirut, Lebanon
  151. Солей Байрактар (Soley Bayraktar), Biruni Univeristy School of Medicine, Protokol Yolu, Istanbul, Turkey
  152. Шэрон Бобер (Sharon Bober), Dana-Farber Cancer Institute, Boston, MA, USA, e-mail: sharon_bober@dfci. harvard.edu
  153. Фатима Кардосо (Fatima Cardoso), Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal, e-mail: fatimacardoso@fundacaochampalimaud.pt
  154. Мария Хоао Кардосо (Maria Joro Cardoso), Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal, e-mail: maria.joao.cardoso@fundacaochampalimaud.pt
  155. Джузеппе Курильяно (Giuseppe Curigliano), IEO, European Institute of Oncology IRCCS, Milano, Italy, Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy, e-mail: giuseppe.curigliano@ieo.it
  156. Элла Эврон (Ella Evrou), Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
  157. Таня Гальярди (Tanja Gagliardi), University of Aberdeen, Aberdeen, UK, e-mail: t.gagliardi@nhs.net
  158. Карен А. Гелмон (Karen A. Gelmon), BC Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada, e-mail: kgelmon@bccancer.bc.ca
  159. Оресте Джентилини (Oreste Gentilini), Breast Unit, San Raffaele University and Research Hospital, Milan, Italy, e-mail: gentilini.oreste@hsr.it
  160. Клара Хангр (Clara Hungr), Cambridge Health Alliance, Cambridge, MA, USA, e-mail: chung@challiance.org
  161. Белла Кауфман (Bella Kaufman), Breast Oncology Institute, Sheba Medical Centre, Ramat Gan, Israel
  162. Асся Консулова (Assia Konsoulova), Medical Oncology Clinic, University Hospital Sveta Marina, Varna, Bulgaria
  163. Маттео Ламбертини (Matteo Lambertini), Department of Medical Oncology, Clinica di Oncologia Medica, Policlinico San Martino-IST, University of Genova, Genoa, Italy
  164. Натали Левассер (Nathalie Levasseur), BC Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada, e-mail: Nathalie.Levasseur@bccancer.bc.ca
  165. Сибилле Лойбль (Sibylle Loibl), German Breast Group, Neu-Isenburg, Germany, Centrum fur Hamatologie und Onkologie Bethanien, Frankfurt am Main, Germany, e-mail: sibylle.loibl@gbg.de
  166. Роза Ди Микко (Rosa Di Micco), Breast Unit, San Raffaele University and Research Hospital, Milan, Italy Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy, e-mail: dimicco.rosa@hsr.it
  167. Бастиен Нгуен (Bastien Nguyen), Breast Cancer Translational Research Laboratory (BCTL), Institut Jules Bordet, UniversithLibre de Bruxelles (ULB), Brussels, Belgium
  168. Оливия Пагани (Olivia Pagani), Institute of Oncology of Southern Switzerland, Geneva University Hospitals, Swiss Group for Clinical Cancer Research (SAKK), and International Breast Cancer Study Group (IBCSG), Lugano, Viganello, Switzerland, e-mail: olivia.pagani@eoc.ch
  169. Шани Палух-Шимон (Shani Paluch-Shimon), Breast Oncology Unit, Shaare Zedek Medical Centre, Jerusalem, Israel, e-mail: shanips@szmc.org.il
  170. Энн Г. Партридж (Ann H. Partridge), Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA, e-mail: ann_partridge@dfci.harvard.edu
  171. Федро А. Пеккатори (Fedro A. Peccatori), Fertility and Procreation Unit, Division of Gynecologic Oncology, European Institute of Oncology, Milan, Italy, e-mail: fedro.peccatori@ieo.it
  172. Филип Д. Порву (Philip D. Poorvu), Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
  173. Джоана Мурато Рибейро (Joana Mourato Ribeiro), Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal, e-mail: joana.ribeiro@fundacaochampalimaud.pt
  174. Джулия X. Роуленд (Julia H. Rowland), Smith Center for Healing and the Arts, Washington, DC, USA Department of Psychiatry, Georgetown University School of Medicine, Washington, DC, USA
  175. Забине Зайлер (Sabine Seiler), German Breast Group, Neu-Isenburg, Germany
  176. Эльжбета Сенкус (Elzbieta Senkus), Department of Oncology & Radiotherapy, Medical University of Gdansk, Gdansk, Poland, e-mail: elsenkus@gumed.edu.pl
  177. Дарио Трапани (Dario Trapani), IEO, European Institute of Oncology IRCCS, Milano, Italy, Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy, e-mail: dario.trapani@ieo.it
  178. Люция Травадо (Luzia Travado), Psycho-Oncology, Neuropsychiatry Unit, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal
  179. Симона Воловат (Simona Volovat), Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
  180. Ринат Ерушалми (Rinat Yerushalmi), Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel, e-mail: rinaty@clait.org.il

В ходе подготовки статей по дерматологии для пользователей сайта МедУнивер - отечественная литература не использовалась.

Редактор: Искандер Милевски. Дата обновления публикации: 1.11.2022
Медунивер Мы в Telegram Мы в VK Форум консультаций врачей Контакты, реклама
Информация на сайте подлежит консультации лечащим врачом и не заменяет очной консультации с ним.
См. подробнее в пользовательском соглашении.